Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
H. Lee Moffitt Cancer Center and Research Institute will be the Sunshine Project Coordinator,
but will not be recruiting locally.
The purpose of this research study is to establish a dose of the combination of drugs,
Topotecan and Sorafenib in children. This will be called the maximum tolerated dose. The
chemotherapy in this study is a combination of Topotecan and Sorafenib. The investigators are
trying to find the highest dose of Topotecan and Sorafenib that can be given safely to
children with Refractory or Recurrent Pediatric Solid Malignancies. The investigators will do
this by testing different doses of these drugs in different groups of children. The
investigators will also study how the body processes these drugs.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
Bayer Pediatric Cancer Foundation
Treatments:
Niacinamide Sorafenib Topoisomerase I Inhibitors Topotecan